Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) (HIPPoS)
|ClinicalTrials.gov Identifier: NCT01096732|
Recruitment Status : Terminated (Slow recruitment)
First Posted : March 31, 2010
Last Update Posted : January 8, 2014
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Ductal Adenocarcinoma||Drug: GDC-0449||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||3 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Proof of Mechanism Study of an Oral Hedgehog Inhibitor (GDC-0449) in Patients With Resectable Pancreatic Ductal Adenocarcinoma in the Pre-operative Window Period|
|Study Start Date :||February 2011|
|Primary Completion Date :||August 2012|
|Study Completion Date :||August 2012|
Gelatine capsules of 150mg.Taken O.D. for 14 days.
Other Name: VISMODEGIB
- To study the effect of GDC-0449 treatment on the stromal cell and tumour cell hedgehog signalling in patients with Pancreatic Ductal Adenocarcinoma. [ Time Frame: 18 months ]
- To study the effect of GDC-0449 treatment on the stromal cell and tumour cell hedgehog signalling in patients with Pancreatic Ductal Adenocarcinoma.
- To study the safety and tolerability of pre-operative GDC-0449 treatment in patients who undergo Whipple's or distal pancreatectomy surgery for Pancreatic Ductal Adenocarcinoma.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01096732
|Cambridge University Hospitals NHS Foundation Trust|
|Cambridge, United Kingdom, CB2 0QQ|
|Principal Investigator:||David Tuveson, MD PhD||Cancer Research UK|